Albireo to Participate at Upcoming Investor Conferences
Albireo Pharma, Inc. (Nasdaq: ALBO) announced that CEO Ron Cooper will present at two upcoming investor conferences: the William Blair 42nd Annual Growth Stock Conference on June 7 at 9:00 a.m. ET, and the Jefferies Healthcare Conference on June 8 at 10:00 a.m. ET. Webcasts of the presentations will be available on Albireo's Investors page for on-demand viewing. Albireo focuses on developing novel bile acid modulators for treating rare liver diseases, with its lead product, Bylvay, approved for pruritus in progressive familial intrahepatic cholestasis.
- None.
- None.
BOSTON, June 02, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer will be presenting at the following investor conferences:
- William Blair 42nd Annual Growth Stock Conference
Tuesday, June 7 at 8 a.m. CT/9:00 a.m. ET
- Jefferies Healthcare Conference
Wednesday, June 8 at 10:00 a.m. ET
The webcasts of the presentations will be available on-demand on the Albireo Investors page ir.albireopharma.com with archives available for 2 months following the events.
About Albireo
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome (ALGS) and biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. In Europe, Bylvay has been approved for the treatment of PFIC with pricing listing in Germany and guidance from the National Institute for Health and Care Excellence (NICE) recommending Bylvay for use in the National Health Service in England, Wales and Northern Ireland. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Media Contact:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lance Buckley, 917-439-2241, lbuckley@lippetaylor.com
Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578
FAQ
What investor conferences is Albireo Pharma presenting at in June 2022?
What time will Ron Cooper's presentations occur?
How can I access the webcasts of Albireo Pharma's presentations?
What is Albireo Pharma's lead product and its indication?
Has Bylvay been approved in Europe?
